This site is intended for healthcare professionals

Mallinckrodt Plc completed its rolling submission of a NDA to the FDA for terlipressin for the treatment of hepatorenal syndrome type 1.

Read time: 1 mins
Published:18th Mar 2020
Condition: Hepato-Renal Syndrome
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest